A phase II study of the PARP Inhibitor, veliparib plus temozolomide in patients with heavily pretreated, metastatic colorectal cancer

BACKGROUND: Poly(ADP-ribose) polymerase (PARP) inhibitors, such as veliparib are potent sensitizing agents and have been safely combined with DNA-damaging agents such as temozolomide. The sensitizing effects of PARP inhibitors are magnified when cells harbor DNA repair defects. METHODS: We performed...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer
Asıl Yazarlar: Pishvaian, Michael J., Slack, Rebecca S, Jiang, Wei, He, A. Ruth, Hwang, Jimmy J., Hankin, Amy, Dorsch-Vogel, Karen, Kukadiya, Divyesh, Weiner, Louis M., Marshall, John L, Brody, Jonathan R.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5992024/
https://ncbi.nlm.nih.gov/pubmed/29579325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.31309
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller